Israel Englander’s Soleno Therapeutics SLNO Stock Holding History

Israel Englander’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-7,000	Closed	-$324K	–	6325
2025 Q4	$324K	Sell	7,000 -61,700	-90%	-$3.38M	﹤0.01%	5218
2025 Q3	$4.64M	Buy	68,700 +43,700	+175%	+$3.24M	﹤0.01%	3219
2025 Q2	$2.09M	Sell	25,000 -40,000	-62%	-$2.99M	﹤0.01%	3839
2025 Q1	$4.64M	Buy	65,000 +50,000	+333%	+$2.43M	﹤0.01%	2936
2024 Q4	$674K	Buy	+15,000	New	+$777K	﹤0.01%	4514

Israel Englander's SLNO Position: Q2 2026 in Review

Israel Englander sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 606,513 shares — an estimated $20.3M sold.

Israel Englander first reported a position in SLNO in Q1 2020 and held it in 17 quarters. The position peaked at $66.2M in Q3 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

Israel Englander reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
Israel Englander sold 606,513 Soleno Therapeutics shares in Q2 2026, an estimated $20.3M.
Israel Englander first reported a position in Soleno Therapeutics in Q1 2020 and held it in 17 quarters.
Israel Englander's Soleno Therapeutics position peaked at $66.2M in Q3 2025.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.